Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22051972 | 0.80 | MEN1 (0.34) | KMT2AMEN1GAATP53MAPT | |
| SCHEMBL21953311 | 0.78 | NOTUM (0.44) | KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL27774816 | 0.76 | KMT2A (0.50) | KMT2AMEN1GAATP53MAPT | |
| SCHEMBL16237002 | 0.76 | BAZ2B (0.49) | KMT2AMEN1GAABAZ2BBAZ2A | |
| SCHEMBL22050833 | 0.75 | MEN1 (0.67) | KMT2AMEN1TP53MAPTPOLB | |
| SCHEMBL1298188 | 0.74 | BAZ2B (0.54) | KMT2AMEN1GAABAZ2BBAZ2A | |
| SCHEMBL3013942 | 0.74 | ALDH1A1 (0.47) | KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL29668460 | 0.73 | KMT2A (0.66) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL2661509 | 0.72 | KMT2A (0.53) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL70354 | 0.72 | BAZ2B (0.71) | GAABAZ2BBAZ2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3888651-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | Kyushu University, National University Corporation (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113164444-A | DOCK1 inhibiting compounds and uses thereof | 国立大学法人九州大学 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | DOCK2, DOCK11, DOCK5 | KMT2A 1929/4885MEN1 1727/4885GAA 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.